Similar articles

• Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials.

  Mian BM. Mian BM. Urol Oncol. 2010 May-Jun;28(3):233-6. doi: 10.1016/j.urolonc.2009.11.011. Epub 2010 Jan 25. Urol Oncol. 2010. PMID: 20097584 No abstract available.
• Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

  Terris MK. Terris MK. Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11. Eur Urol. 2009. PMID: 18353530 No abstract available.
• Efficacy vs effectiveness in prostate-specific antigen screening.

  Albertsen PC. Albertsen PC. J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8. J Natl Cancer Inst. 2010. PMID: 20142583 No abstract available.
• [Screening for prostate cancer--what does the evidence show?].

  Borre M, Iversen P. Borre M, et al. Ugeskr Laeger. 2007 May 14;169(20):1887-8. Ugeskr Laeger. 2007. PMID: 17553362 Review. Danish.
• Prostate cancer screening.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2008 Nov 3;50(1298):85-6. Med Lett Drugs Ther. 2008. PMID: 18978703 Review. No abstract available.